RADIOTHERAPY ALONE WITH CURATIVE INTENT IN PATIENTS WITH STAGE I EXTRANODAL NASAL-TYPE NK/T-CELL LYMPHOMA
RADIOTHERAPY ALONE WITH CURATIVE INTENT IN PATIENTS WITH STAGE I EXTRANODAL NASAL-TYPE NK/T-CELL LYMPHOMA
复制标题
单纯放疗对 I 期结外鼻型 NK/T 细胞淋巴瘤患者具有治愈作用
DOI：
10.1016/j.ijrobp.2010.10.040
复制
发表时间：
2012-04-01
影响因子：
7
通讯作者：
Yu, Zi-Hao
中科院分区：
文献类型：
--
作者：
Li, Ye-Xiong;Wang, Hua;Yu, Zi-Hao
用途：本研究的目的是评估的结果和模式失败的一个大型队列的患者I期NK/T细胞淋巴瘤的上呼吸消化道放疗单独治疗。方法和材料：病理诊断证实使用标准的标准。所有患者均单独接受大剂量扩大野放射治疗。中位剂量为50戈伊。结果：87例患者中，85例（97.7%）有效率为95.4%（85/87），部分有效率为2.3%（85/87）。所有患者的5年总生存率、无进展生存率和局部控制率分别为80%、69%和93%。20例患者（23%）出现疾病进展或复发。其中，15例（17%）开发系统的淋巴结播散，而只有4（5%）例患者局部复发和4（5%）例淋巴结revolution.Conclusions：我们的研究表明，高剂量的扩展野放疗单独是一种治愈性治疗，并显示良好的临床结果与I期疾病的患者。由于局部控制的可能性很高，全身播散的原发性失败，最佳放射治疗与更有效的系统治疗相结合，有必要为这些患者带来额外的改善。(c)2012 Elsevier Inc.
Purpose: This study aims to evaluate the outcome and pattern of failure in a large cohort of patients with Stage I NK/T-cell lymphoma of the upper aerodigestive tract treated with radiotherapy alone.Methods and Materials: The pathological diagnosis was confirmed using standard criteria. All patients were treated with high-dose extended-field radiotherapy alone. The median dose was 50 Gy. The primary tumor was located in the nasal cavity (n = 80), Waldeyer ring (n = 5), or oral cavity (n = 2).Results: The overall response to radiotherapy was achieved in 85 of 87 (97.7%) patients, with a complete response rate of 95.4% and a partial response rate of 2.3%. The 5-year overall survival, progression-free survival, and local control rates for all patients were 80%, 69%, and 93%, respectively. Twenty patients (23%) had disease progression or relapse. Of these, 15 patients (17%) developed systemic extranodal disseminations, whereas only 4 (5%) patients had local relapse and 4 (5%) patients had lymph node relapse.Conclusions: Our study suggests that high-dose extended-field radiotherapy alone is a curative therapy and shows favorable clinical outcome in patients with Stage I disease. With the high possibility of local control and primary failure of systemic dissemination, the integration of optimal radiotherapy with more effective systematic therapy is warranted to bring additional improvement to the outcome for these patients. (c) 2012 Elsevier Inc.